All Articles
In a series of interviews conducted at ASCO 2025, our Kristin Siyahian, VP, Branded Channels, spoke with some key leaders in oncology and heard their thoughts on what trends and therapies will be shaping future oncology care. We present a summary of a few interviews in that series, and we encourage you to listen to the full podcast interviews at www.oncpracticemanagement.com/voices-from-asco-2025. Read More ›
A coalition of more than 40 health insurers recently announced plans for prior authorization reform. Read More ›
Iman Ahmed, PharmD, BCOP, recently discussed the evidence for what’s actually contributing to health inequities in hematologic malignancies, and how providers can mitigate these disparities. Read More ›
In the United States, between 2006 and 2015, there were approximately 2000
new cases of Merkel cell carcinoma annually, with totals expected to exceed
3200 in 2025. Read More ›
Achieving cancer health equity requires combined structural reforms and individual-level support, along with sustained, collaborative commitment. Read More ›
Both single-agent retifanlimab-dlwr (Zynyz; Incyte) and use with carboplatin and paclitaxel have been greenlit for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. Read More ›
Darolutamide (Nubeqa; Bayer Healthcare Pharmaceuticals) has been approved by the FDA for metastatic castration-sensitive prostate cancer (mCSPC), following an earlier approval to be used in combination with docetaxel for mCSPC. Read More ›
Officials with the FDA recently approved belzutifan (Welireg; Merck) for people aged ≥12 years with locally advanced unresectable or metastatic pheochromocytoma or paraganglioma (PPGL), making it the first FDA approval of an oral therapy for PPGL. Read More ›
On June 11, 2025, officials with the FDA approved taletrectinib (Ibtrozi; Nuvation Bio), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non–small cell lung cancer. Read More ›
Mitomycin intravesical solution (Zusduri; UroGen Pharma) may now be used to treat adult patients with recurrent intermediate-risk, low-grade, non-muscle invasive bladder cancer after an FDA approval in June. Read More ›